Vestal Point Capital, LP
Q2 2025 13F Holdings
- Locationnew york, NY
- Num holdings
72
- Value ($000)
$1,899,347
- Date Filed08/14/2025
- Form type13F-HR
- CIK0001974915
- All SEC filings
- NoteHoldings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q2 2025 toSelect Quarter
Issuer Name | Class | CUSIP | VALUE | % | Shares | Principal | Option Type |
|---|---|---|---|---|---|---|---|
ACLX Arcellx Inc | COMMON STOCK | 03940C100 | $181.09M | 10 % | 2,750,000 | ||
Jazz Pharmaceuticals PLC | SHS USD | G50871105 | $127.34M | 7 % | 1,200,000 | ||
CYTK Cytokinetics Inc | COM NEW | 23282W605 | $98.29M | 5 % | 2,975,000 | ||
NUVL Nuvalent Inc | COM | 670703107 | $82.02M | 4 % | 1,075,000 | ||
VERA Vera Therapeutics Inc | CL A | 92337R101 | $73.04M | 4 % | 3,100,000 | ||
FOLD Amicus Therapeutics Inc | COM | 03152W109 | $68.19M | 4 % | 11,900,000 | ||
Xenon Pharmaceuticals Inc | COM | 98420N105 | $62.60M | 3 % | 2,000,000 | ||
DNTH Dianthus Therapeutics Inc | COM | 252828108 | $59.62M | 3 % | 3,200,000 | ||
SRRK Scholar Rock Holding Corp | COM | 80706P103 | $53.13M | 3 % | 1,500,000 | ||
KALV KalVista Pharmaceuticals Inc | COM | 483497103 | $52.85M | 3 % | 4,675,000 |
Rows Per Page
10
- 10
- 50
- 100